Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 10/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21206316 | 0.95 | SMYD3 (0.40) | GLSGLAMAPK1SMYD3CYP2C19 | |
| SCHEMBL25447013 | 0.91 | GLA (0.37) | GLSGLAMAPK1SMYD3CYP2C19 | |
| SCHEMBL24125043 | 0.91 | SMYD3 (0.37) | GLSGLAMAPK1SMYD3CYP2C19 | |
| SCHEMBL23943180 | 0.87 | MAPK1 (0.36) | GLSGLAMAPK1SMYD3CYP2C19 | |
| SCHEMBL26409868 | 0.81 | CYP2C19 (0.42) | GLSCYP2C19ALDH1A1LMNA | |
| SCHEMBL21538183 | 0.72 | MEN1 (0.56) | CYP2C19MEN1TSHRKMT2AALDH1A1 | |
| SCHEMBL20046976 | 0.71 | ALDH1A1 (0.52) | GLSGLAMAPK1MEN1TSHR | |
| SCHEMBL21206323 | 0.70 | CYP2C19 (0.35) | GLSCYP2C19ALDH1A1LMNA | |
| SCHEMBL15274453 | 0.68 | LMNA (0.47) | GLSMAPK1CYP2C19TSHRKMT2A | |
| SCHEMBL4782298 | 0.68 | SMYD3 (0.40) | GLSGLAMAPK1SMYD3CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230147312-A1 | TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME AND RELATED CONDITIONS WITH ANTAGONISTS OF E-SELECTIN | GLYCOMIMETICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230147312-A1 | TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME AND RELATED CONDITIONS WITH ANTAGONISTS OF E-SELECTIN | SELP, SELE, SELPLG | GLS 2741/4885GLA 1222/4885MAPK1 3462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.